Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 9/20 | 0.64 |
| ▸ | KCNJ5 | P48544 | 9/20 | 0.64 |
| ▸ | KCNJ3 | P48549 | 9/20 | 0.64 |
| ▸ | GRM5 | P41594 | 6/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080035 | 0.95 | PTPN1 (0.59) | KCNJ6KCNJ5KCNJ3GRM5NTRK1 | |
| SCHEMBL6079824 | 0.89 | PTPN1 (0.50) | KCNJ6KCNJ5KCNJ3GRM5NTRK1 | |
| SCHEMBL6079684 | 0.87 | MAPK13 (0.60) | KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL6079909 | 0.81 | MAPK14 (0.56) | — | |
| SCHEMBL6206171 | 0.80 | ELOVL1 (0.48) | KCNJ6KCNJ5KCNJ3LMNA | |
| SCHEMBL6079289 | 0.80 | MAPK14 (0.59) | — | |
| SCHEMBL6233788 | 0.80 | FLT3 (0.53) | KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL6080298 | 0.80 | MAPK14 (0.56) | — | |
| SCHEMBL6079119 | 0.80 | ALDH1A1 (0.52) | LMNA | |
| SCHEMBL6080417 | 0.79 | KCNJ6 (0.44) | KCNJ6KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | KCNJ6 3728/4885KCNJ5 4159/4885KCNJ3 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.